PhaseRx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PZRXQ research report →
Price Chart
About the company
PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments for inherited enzyme deficiencies affecting the liver. Its therapeutic strategy involves intracellular enzyme replacement, powered by its unique Hybrid mRNA technology platform, which facilitates the production of absent enzymes directly within the body's cells.
- CEO
- Robert W. Overell
- IPO
- 2016
- Employees
- 10
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on PZRXQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.17K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 101.72%
- ROIC
- -122.20%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-18,330,000
- Net Income
- $-20,137,000-173.0%
- EPS
- $-2.68-185.1%
- OCF Growth
- -64.1%
- FCF Growth
- -63.8%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.55
- RSI (14)
- 52
- Avg Volume
- 213
No earnings-call transcripts are available for PZRXQ yet.
- Free Float
- 100.0%
- Shares Outstanding
- 11.69M
- Float Shares
- 11.69M
Our PZRXQ coverage
Recent articles, reports, and earnings notes.
No research on PZRXQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PZRXQ report →